Phospho-Pim1 (Tyr309) Antibody

What is the significance of Pim-1 Tyr309 phosphorylation in cancer research?

Pim-1 (Proviral integration site for Moloney murine leukemia virus 1) is a serine/threonine kinase that plays critical roles in cell proliferation, survival, and drug resistance. Phosphorylation at Tyr309 appears to be a marker of Pim1 kinase activity and has significant implications in cancer biology. Research shows that HER2-overexpressing breast cancer cells with increased Pim1 Tyr309 phosphorylation are more sensitive to Pim1 inhibitors, and lapatinib-resistant cancer cells exhibit higher Pim1 kinase activity evidenced by increased phosphorylation at this site . This phosphorylation also affects Pim-1's ability to regulate receptor tyrosine kinases, including EGFR, HER2, and HER3, potentially contributing to treatment resistance mechanisms.

Methodologically, researchers can use Phospho-Pim1 (Tyr309) antibodies to:

• Track treatment response to Pim-1 inhibitors

• Study resistance mechanisms to tyrosine kinase inhibitors

• Evaluate cross-talk between Pim-1 and HER2 signaling pathways

What are the optimal experimental conditions for detecting Phospho-Pim1 (Tyr309) in Western blot applications?

For optimal detection of Phospho-Pim1 (Tyr309) in Western blot applications:

• Sample preparation: Use freshly prepared cell lysates from actively growing cells. Phosphorylation states can degrade rapidly, so immediate sample processing with phosphatase inhibitors is crucial.

• Antibody dilution: Most Phospho-Pim1 (Tyr309) antibodies work optimally at 1:500-1:2000 dilution range for Western blotting .

• Protein loading: Load 20-50 μg of total protein per lane.

• Blocking: Use 5% BSA in TBST rather than milk (which contains phosphatases).

• Detection: Secondary antibody concentration should be optimized, typically 1:5000-1:10000 dilution.

• Controls: Include both phosphorylated (positive control) and non-phosphorylated (negative control) samples.

According to validation data, the expected molecular weight of Pim-1 is approximately 36 kDa (calculated) .

What cell types are most suitable for studying Phospho-Pim1 (Tyr309)?

Based on the research literature, these cell types are particularly suitable for Phospho-Pim1 (Tyr309) studies:

• HER2-overexpressing breast cancer cells: SkBr3, BT474, and HER2-transformed cell lines (HER18, T47D-HER2) show high Pim-1 activity and pronounced sensitivity to Pim-1 inhibitors .

• Prostate cancer cell lines: DU145, PC3, and LNCaP express substantial levels of Pim-1, with documented phosphorylation at Tyr309 .

• Hematopoietic cancer cells: K562 and U937 (TPA-treated) exhibit high levels of surface-associated Pim-1, making them valuable for studying membrane localization of phosphorylated Pim-1 .

• Lapatinib-resistant cells: Sk/LR6 and Sk/LR9 (lapatinib-resistant clones of SkBr3) display elevated Pim1 kinase activity with increased Tyr309 phosphorylation compared to parental cells .

Methodologically, researchers should verify Pim-1 expression levels in their cell lines of interest before proceeding with phosphorylation studies.

How can researchers distinguish between Pim-1 autophosphorylation and phosphorylation by upstream kinases?

Distinguishing between Pim-1 autophosphorylation and phosphorylation by upstream kinases requires multiple complementary approaches:

• In vitro kinase assays:

  • Express recombinant Pim-1 with kinase-dead mutations (e.g., K67M)

  • Compare phosphorylation patterns between wild-type and kinase-dead mutants

  • Presence of Tyr309 phosphorylation in kinase-dead mutants would indicate an upstream kinase is responsible

• Pharmacological approach:

  • Treat cells with Pim-1 specific inhibitors (e.g., SMI-4a)

  • Monitor changes in Tyr309 phosphorylation

  • Persistent phosphorylation despite Pim-1 inhibition suggests upstream kinase involvement

• Mass spectrometry:

  • Compare phosphorylation sites identified in heterologously expressed Pim-1 (e.g., in E. coli) versus mammalian cells

  • Phosphorylation sites present only in mammalian cells may indicate upstream kinase activity

Research has suggested potential autophosphorylation of Pim-1 at several residues (Ser190, Thr205, Ser261), but the specific mechanism of Tyr309 phosphorylation remains under investigation .

What is the relationship between HER2 signaling and Pim-1 Tyr309 phosphorylation in drug resistance mechanisms?

The relationship between HER2 signaling and Pim-1 Tyr309 phosphorylation in drug resistance presents a complex bidirectional regulatory mechanism:

• HER2 regulation of Pim-1:

  • HER2 expression strongly correlates with Pim-1 expression in breast cancer

  • HER2-overexpressing cells show increased sensitivity to Pim-1 inhibitors

  • This suggests HER2 signaling may promote Pim-1 activity and phosphorylation

• Pim-1 regulation of HER2:

  • Pim-1 inhibitors suppress HER2 expression at the transcriptional level

  • Pim-1 inhibition can overcome resistance to HER2 tyrosine kinase inhibitor lapatinib

• Phospho-Tyr309 in resistance mechanisms:

  • Lapatinib-resistant cells (Sk/LR6 and Sk/LR9) exhibit higher Pim1 kinase activity with increased Tyr309 phosphorylation

  • Tumoral Pim1 mRNA expression was higher in lapatinib-treated patients with HER2-positive breast cancers than in patients without lapatinib treatment

This suggests a feedback loop where HER2 inhibition leads to compensatory increases in Pim-1 activity (evidenced by Tyr309 phosphorylation), which in turn maintains HER family expression even in the presence of HER2 inhibitors. Experimentally, this relationship can be investigated by:

• Combination treatment with Pim-1 and HER2 inhibitors

• Time-course analysis of Tyr309 phosphorylation after HER2 inhibition

• Genetic manipulation of Pim-1 levels in HER2-dependent cells

How can Phospho-Pim1 (Tyr309) antibodies be utilized in cell-based high-throughput screening for novel Pim-1 inhibitors?

Cell-based high-throughput screening for Pim-1 inhibitors using Phospho-Pim1 (Tyr309) antibodies involves several methodological considerations:

• Assay format selection:

  • Cell-based ELISA offers higher throughput and quantitative results

  • Available kits provide optimized protocols with multiple normalization options

• Cell line selection:

  • Choose cell lines with high baseline Pim-1 Tyr309 phosphorylation (e.g., HER2-overexpressing breast cancer cells)

  • Cancer cell lines with documented Pim-1 dependency show greater signal dynamic range

• Assay optimization:

  • Determine optimal cell density (typically >5000 cells per well)

  • Establish treatment time courses (4-24 hours for acute effects)

  • Include known Pim-1 inhibitors as positive controls (e.g., SMI-4a)

• Data analysis and normalization:

  • Normalize phospho-signal to total Pim-1 levels

  • Utilize GAPDH as internal control

  • Implement Crystal Violet staining to correct for cell number variations

• Secondary validation:

  • Confirm hits with orthogonal methods (Western blot)

  • Evaluate effects on downstream targets (BAD, CDC25A, MYC)

  • Assess functional outcomes (proliferation, survival, drug resistance)

This approach enables efficient screening of compound libraries to identify molecules that reduce Pim-1 Tyr309 phosphorylation, potentially indicating inhibition of Pim-1 kinase activity.

What techniques can be used to study the compartment-specific phosphorylation status of Pim-1 at Tyr309?

Studying compartment-specific Pim-1 Tyr309 phosphorylation requires specialized techniques to distinguish between cytoplasmic, nuclear, and membrane-associated forms:

• Subcellular fractionation:

  • Separate nuclear, cytoplasmic, and membrane fractions using differential centrifugation

  • Analyze phosphorylation status in each fraction by Western blot

  • Include compartment-specific markers (e.g., Na⁺/K⁺-ATPase for membrane, GAPDH for cytoplasm, Lamin B for nucleus)

• Immunofluorescence microscopy:

  • Use FITC-conjugated phospho-specific antibodies for direct visualization

  • Perform co-localization studies with compartment markers

  • Document linear or clustered cell surface staining patterns as reported in cancer cells

• Cell surface biotinylation:

  • Label cell surface proteins with Sulfo-NHS-LC-Biotin

  • Immunoprecipitate with Phospho-Pim1 (Tyr309) antibody

  • Analyze by Western blot to confirm cell surface localization

• Proximity ligation assay (PLA):

  • Detect in situ interactions between Phospho-Pim1 (Tyr309) and compartment-specific proteins

  • Quantify phosphorylation events in specific cellular locations

Research has shown that Pim-1 exhibits differential subcellular distribution: Isoform 1 is found in cytoplasm and nucleus, while Isoform 2 localizes to the cell membrane . Understanding compartment-specific phosphorylation provides insights into Pim-1's diverse functions across cellular locations.

How does Phospho-Pim1 (Tyr309) status correlate with inflammatory signaling pathways?

The relationship between Phospho-Pim1 (Tyr309) and inflammatory signaling pathways reveals important regulatory mechanisms:

• Pim-1 in pro-inflammatory signaling:

  • Pim-1 knockdown in macrophage-like THP-1 cells suppresses LPS-induced pro-inflammatory cytokines

  • Affects multiple inflammatory pathways: JAK/STAT3, MAPK (ERK, JNK, p38), and NF-κB signaling

  • Inhibits NLRP3 inflammasome activation and caspase-1 cleavage

• Mechanistic interactions:

  • Phosphorylated transforming growth factor-β-activated kinase 1 (p-TAK1) directly interacts with Pim-1

  • This interaction may represent a critical node in inflammatory signaling cascades

  • Pim-1 phosphorylation status potentially regulates this interaction

• Experimental approaches to study this relationship:

  • Stimulate cells with inflammatory triggers (LPS, cytokines) and monitor Tyr309 phosphorylation

  • Use phosphorylation-specific antibodies to track activation in response to inflammatory stimuli

  • Employ Pim-1 inhibitors to determine effects on downstream inflammatory markers

• Data interpretation considerations:

  • Compare phosphorylation timing with activation of NF-κB, STAT3, and MAPK pathways

  • Evaluate dose-dependent relationships between inflammatory stimuli and Pim-1 phosphorylation

  • Consider cell-type specific differences in Pim-1's role in inflammation

This relationship suggests Phospho-Pim1 (Tyr309) antibodies could be valuable tools for studying inflammation-associated diseases and developing anti-inflammatory therapeutics targeting Pim-1.

What are the key considerations when validating a new Phospho-Pim1 (Tyr309) antibody for research applications?

Validating a new Phospho-Pim1 (Tyr309) antibody requires rigorous testing across multiple parameters:

• Specificity validation:

  • Compare reactivity against phosphorylated vs. non-phosphorylated peptides

  • Test with phosphatase-treated samples as negative controls

  • Verify recognition of endogenous Pim-1 only when phosphorylated at Tyr309

  • Confirm absence of cross-reactivity with other proteins

• Sensitivity assessment:

  • Determine lower limit of detection with serial dilutions

  • Compare signal-to-noise ratio across different sample types

  • Establish optimal antibody concentrations for different applications

• Application-specific validation:

  • Western blot: Verify single band at expected molecular weight (~36 kDa)

  • ELISA: Establish standard curves and determine dynamic range

  • Immunofluorescence: Confirm expected subcellular localization patterns

• Cross-species reactivity:

  • Test antibody performance across human, mouse, and rat samples

  • Note potential differences in phosphorylation site positioning (Human: Tyr309, Mouse: Tyr302, Rat: Tyr218)

• Reproducibility testing:

  • Repeat experiments with different biological replicates

  • Test lot-to-lot consistency when possible

• Experimental controls:

  • Positive controls: Samples known to express phosphorylated Pim-1 (e.g., HER2-overexpressing cells)

  • Negative controls: Samples treated with Pim-1 inhibitors or phosphatases

  • Competing peptide controls: Pre-incubation with immunizing phosphopeptide should abolish signal

Documentation of these validation steps ensures reliable and reproducible results when using Phospho-Pim1 (Tyr309) antibodies in research applications.